Showing 1-10 of about 1107 articles.
Oncology Venture A/S
Hørsholm, Denmark (29 June 2020) – Oncology Venture A/S (“OV” or the “Company”) today announced that it has signed a definitive agreement out-licensing two clinical pipeline assets, LiPlaCis® and...
Mateon Therapeutics
The licensing agreement of OT-101 to Autotelic BIO with the field of use limited to OT-101 (Trabedersen) with Interleukin-2 (OT-101/IL-2) combination became effective this week with the completion of...
NewLink Genetics Corporation
AMES, Iowa, Dec. 23, 2019 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that the company has entered into an exclusive worldwide license agreement with Ellipses...
MacroGenics, Inc.
ROCKVILLE, MD, and SHANGHAI, China, July 10, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative...
ChromaDex Corporation
LOS ANGELES, Dec. 20, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC) announced today it entered into a license and supply agreement with Nestlé Health Science (NHSc), a global leader...
The Premiere Group
New York, New York, Dec. 11, 2018 (GLOBE NEWSWIRE) -- The Premiere Group, a wholly owned subsidiary of the Perfume Center of America Inc., has acquired the Derek Lam Beauty license, in a multi-year...
MacroGenics, Inc.
Comprehensive collaboration across three MacroGenics’ pipeline programs to accelerate and expand ongoing developmentExpand Zai Lab’s late-stage clinical pipeline with margetuximab and obtain rights to...
Arbutus Biopharma Corporation
Two Novel HBV Candidates Planned to Enter Clinical Development in 2018GalNAc Conjugated RNAi Agent Nominated to Enter IND-Enabling Studies Strategic Partnership with Roivant to Launch Genevant, an RNA...
Apricus Biosciences, Inc.
FDA Confirms Vitaros Regulatory Pathway Company Seeking Partner to Develop Vitaros in U.S. Company Evaluating Strategic Alternatives SAN DIEGO, April 16, 2018 (GLOBE NEWSWIRE) -- Apricus...
Arbutus Biopharma Corporation
Genevant aims to advance 5-10 product candidates into the clinic by 2020 across RNAi, mRNA, and gene editing modalities using Arbutus’ LNP and ligand conjugate platformsGenevant will be led by...
Showing 1-10 of about 1107 articles.
